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Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The NetherlandsBackground & Aims: Predniso(lo)ne with or without azathioprine Conclusions: Based on available RCTs, PRED monotherapy and
is considered the mainstay in the treatment of autoimmune hep-
atitis (AIH), but many therapeutic options are available. The pri-
mary objective of this review was to explore the published
literature on the optimal induction and subsequent maintenance
therapy for AIH.
Methods:We performed a systematic search on electronic dat-
abases MEDLINE (1950-07.2009), Web of Science, Cochrane, and
the website www.clinicaltrials.gov. Randomized controlled trials
(RCTs) on apparent beneﬁcial treatment regimens as induction
or maintenance treatment in AIH were included. Pediatric studies
were excluded. We calculated relative risks (RR) for comparison of
treatment options on the primary outcome measure, which was
deﬁned as clinical, biochemical and histological remission.
Results: Eleven RCTs were included, of which 7 studies evaluated
the induction therapy in AIH patients: 3 treatment naive (n = 253),
2 relapse (n = 53), 2 combination of naive and relapse (n = 110).
The remaining 4 studies (n = 162) assessed maintenance therapy.
All but one maintenance study (thymostimulin versus no therapy)
studied predniso(lo)ne (PRED), azathioprine (AZA) or combination
PRED + AZA. We found no differences in primary outcome
between induction therapy with PRED and PRED + AZA in treat-
ment naive patients (RR = 0.98; 95% CI 0.65–1.47). AZA mono-
therapy as induction was considered as not viable because of a
high mortality rate (30%). This was similar in AIH patients who
relapsed: RR for PRED versus PRED + AZA for inducing remission
was not different: 0.71 (95% CI 0.37–1.39). PRED + AZAmaintained
remission more often than PRED (RR = 1.40; 95% CI 1.13–1.73).
Also AZA maintained a higher remission rate than PRED
(RR = 1.35; 95% CI 1.07–1.70). Maintenance of remission was not
different between PRED + AZA and AZA (RR = 1.06; 95% CI 0.94–
1.20).Journal of Hepatology 2
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Autoimmune hepatitis (AIH) is a rare chronic progressive liver dis-
ease of unknown etiology [1]. Clinical presentation may include
fatigue, pain in the right upper quadrant of the abdomen, polym-
yalgia, and arthralgia involving small joints [1]. The disease pre-
dominantly affects women and occurs in children and adults of
all ages. The estimated annual incidence of AIH among Northern
Europeans is 1.9 cases per 100,000 persons per year [1,2]. The clin-
ical picture is heterogeneous and in absence of a single clinical or
biochemical test, diagnosis is made according to a set of clinical
criteria developed in 1993, which were revised in 1999 and sim-
pliﬁed in 2008 [3–5]. These diagnostic criteria include (1) hyper-
gammaglobulinaemia; (2) the presence of particular
autoantibodies, i.e., ANA, SMA or anti-LKM1; (3) liver histology
features similar to chronic hepatitis of other etiology; (4) the
absence of viral and toxic hepatitis or other conditions that may
resemble AIH [5,6]. Based on this set of criteria, the sensitivity
of the scoring system for AIH ranges from 97% to 100%, and its
speciﬁcity for excluding AIH in patients with chronic hepatitis C
ranges from 66% to 92% [6].
Three randomized controlled trials (RCTs) dating from the
1970s have established the effect of immunosuppressive drugs
for AIH [7–9]. Predniso(lo)ne monotherapy (PRED) or a combina-
tion of predniso(lo)ne and azathioprine (PRED + AZA) was superior
to other treatment options, including titrating PRED, in improving
liver function and life expectancy [7–9]. The current recommenda-
tions for AIH therapy originate from this era, and PRED, usually in
combination with AZA, is considered the mainstay of therapy. In
some cases cirrhosis develops despite treatment; in other cases,
treatment discontinuation or dose reduction is necessary because
of intolerable adverse events. This has fueled the search for treat-
ment alternatives.
Our primary objective was to explore the published literature
on evidence of optimal induction and subsequent maintenance010 vol. 53 j 191–198
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therapy for AIH. We therefore performed a systematic review and
examined all RCTs for treatment of AIH published from 1950 until
present.Clinicaltrials.gov
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Fig. 1. Flowchart of included and excluded articles in the systematic literature
search.Methods
Literature search
We performed a systematic literature search using a set of electronic databases:
MEDLINE (1950-07.2009), Web of Science, Cochrane, and the website www.
clinicaltrials.gov to identify all published articles and abstracts, and ongoing
studies from 1950 until July 2009. The following terms were used: ‘hepatitis’,
‘autoimmune’ and ‘clinical trial’. All papers published before August 2009 were
eligible.
Selection of studies
We employed a 2-stage approach. First, we excluded all articles that were not
written in English, German, French or Spanish. We subsequently removed all
duplicates, and screened remaining articles on the basis of title and abstract. Only
RCTs were included: case reports, case series, review articles, letters, and editorials
were excluded. Studies not evaluating the efﬁcacy of therapy for AIH in adult
patients (age P18 years) were rejected. Subsequently, full text screening was
applied to the remaining studies. Articles were systematically reviewed on the
basis of their inclusion criteria and methodological aspects by two independent
reviewers (ML, MP). Discrepancies were solved by discussion with a third party
(JD). In order to check whether our search included all published papers that were
possibly relevant for this review, we scrutinized reference lists of included articles.
This strategy was adopted because of evolving deﬁnition of AIH prior to 1993.
Outcomes
Remission was considered as the primary outcome measure. We deﬁned remission
following recently published criteria: disappearance of symptoms; normal serum,
bilirubin, and c-globulin levels; serum aminotransferase level normal or less than
twice normal; normal hepatic tissue or minimal inﬂammation and no interface
hepatitis [10]. For each individual article, we evaluated all available outcomes that
matched the criteria of our user deﬁnition of remission. For example, if liver biopsy
was not an outcome described in a particular article, we applied all other pre-
sented outcomes, such as clinical and biochemical variables, in order to achieve
the most appropriate deﬁnition of remission for that study.
The secondary outcome measures included mortality and occurrence of
adverse events. All outcomes were extracted from the included trials and were
assessed at maximum follow-up.
Clinical trials in the treatment of AIH can be divided in 2 categories (1) trials
that assess the effect of induction therapy in newly identiﬁed or relapsed AIH
patients (induction trials); (2) trials that have been performed during remission
in order to compare the efﬁcacy of two immunosuppressive regimens with main-
tenance of remission as the primary endpoint (maintenance trials).
Quality of the included studies was assessed, based on a well-established, val-
idated scale developed by Jadad et al. [11]. The Jadad score gives a numerical score
between 0 and 5 as a rough measure of clinical trial design/reporting quality (0
being weakest and 5 being strongest).
Extraction of data
After inclusion, we extracted data from each article and entered characteristics of
trials, patients, and interventions, as well as the primary and secondary outcome
measures. Trial characteristics included the ﬁrst author’s name, year and journal
of publication, study design, type, dose and duration of applied therapy, and length
of follow-up. Patient characteristics comprised inclusion and exclusion criteria,
mean age, number of patients randomized, and number and reasons for dropouts
and withdrawals.
Data on all patients, irrespective of compliance or follow-up were sought to
allow intention-to-treat analyses. In this analysis the total number of patients ran-
domized is the number of patients included in the efﬁcacy analysis. We used data
related to initial therapy and relevant to maintenance therapy. In case data were
recorded immediately at the end of the evaluation period, this was preferred to fol-192 Journal of Hepatology 20low-up data. In case of missing outcome values at the end of the evaluation period,
due to premature withdrawal of therapy in patients with deterioration or drug
intolerance, last measured values of outcome were substituted for missing values.
In order to evaluate adverse events related to therapy for AIH, data regarding
adverse events in patients treated with the interventional drug(s) were extracted.
In addition, data about deterioration in all patients reported in the included stud-
ies, were extracted.
Synthesis of data and analysis
In this review, a brief overview of the interventions and number of patients in the
trials is given for each separate study. In addition, we pooled patient data from all
studies and stratiﬁed them in different subgroups according to induction and
maintenance therapy, applied intervention and obtaining remission, mortality or
complications. This was done in order to determine the efﬁcacy of the interven-
tional drugs in terms of induction of favorable outcome in each of the different
therapy groups.10 vol. 53 j 191–198
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We calculated overall frequencies for the primary outcome measure expressed
as percentages. Furthermore, frequencies and percentages for the secondary out-
come measures, reported mortality and adverse events were calculated.
Data were stored in Reference Manager 11 and Excel database software for
Windows XP. Due to heterogeneity of studies, we have focused on descriptive
analysis and overall frequencies of favorable outcomes were determined by sam-
ple sized weighted pooled proportion. In order to quantify the differences between
frequently studied treatment strategies we pooled the data and calculated relative
risk with 95% conﬁdence interval.Results
Literature search and selection of studies
The results of our systematic literature search and subsequent
selection of articles are summarized in a ﬂow diagram (Fig. 1).
The search identiﬁed 302 different studies, of which we excluded
247 studies due to study aims; 49 studies were rejected because of
study design. Full text screening was applied for 6 articles, and all
fulﬁlled the selection criteria. Of these articles, the reference lists
were checked, and this strategy resulted in 5 additional articles
that fulﬁlled the inclusion criteria. Thus, a total of 11 RCTs were
included for further analyses [7–9,12–19] of which 7 studies eval-
uated the induction therapy in AIH patients: 3 treatment naive
(n = 253), 2 relapse (n = 53), 2 combination of naive and relapse
(n = 110). The remaining 4 studies (n = 162) assessed maintenance
therapy.
Many drugs were studied, and we analyzed the most viable
options: PRED, AZA or a combination of both. Outcome assess-
ments in patients treated within the different treatment arms
were made after an evaluation period of >3 months, the meanTable 1. Induction therapy in naive patients with autoimmune hepatitis.
First author, journal, year Intervention
Cook, Quarterly,
Journal of Medicine, 1971
Prednisolone 15 mg/day
No intervention
Soloway, Gastroenterology, 1972 Prednisone 60 mg/day 1 week, 40 mg/day
1 week, 30 mg/day 2 weeks, 20 mg/day maintena
Azathioprine 100 mg/day
Prednisone 30 mg/day 1 week, 20 mg/day
1 week, 15 mg/day 2 weeks, 10 mg/day
maintenance + azathioprine 50 mg/day
Placebo
Murray-Lyon, Lancet, 1973 Prednisone 5 mg 3dd
Azathioprine 75 mg 1dd
Summerskill, Gut, 1975 Prednisone 60 mg/day 1 week, 40 mg/day
1 week, 30 mg/day 2 weeks, 20 mg/day maintena
Prednisone 30 mg/day 1 week, 20 mg/day
1 week, 15 mg/day 2 weeks, 10 mg/day
maintenance + azathioprine 50 mg/day
Prednisone in titrated doses given on
alternate days
Placebo/azathioprine 100 mg/day
Tage-Jensen, Liver, 1982 Azathioprine 10 mg/kg/week, ﬁrst 2 weeks
5 mg/kg/week
Prednisone <70 kg 10 mg/day, P70 kg 15 mg/day
* Ninety-nine autoimmune patients, information provided for 84 patients only. 34 patie
treated with prednisone died before 1 year of treatment, while 10 patients died in the
Journal of Hepatology 20evaluation period was comparable for the different groups, and
varied between 1 and 2 years.
Induction therapy in treatment naive AIH patients
We retrieved 5 studies, published between 1971 and 1982, that
assessed the clinical outcome of AIH in drug naive patients
(Table 1). These 5 studies included 363 patients in 6 different
arms, 26% were male [7–9,17,18]. The calculated Jadad score for
these studies ranged between 1 and 4. Two studies performed a
head-to-head comparison between PRED and AZA [9,17]. One
study evaluated the treatment with PRED, PRED + AZA, titrated
PRED and placebo or AZA [18]. Another trial studied the same
drugs but titrated PRED [8]. One study compared PRED with no
intervention [7]. Applied dosages varied between 10 and 60 mg
daily of PRED (maintenance dose 10–20 mg/day) [7–9,17,18] and
between 50 and 100 mg daily of AZA [8,9,17,18].
Ninety-ﬁve patients were treated with PRED (not titrated),
remission occurred in 42% [8,17,18]. We were not able to extract
remission rates in two studies, as they contained only minimal
information [7,9]. The mortality rate was 15% (21/139) (Fig. 2A)
[7–9,17,18].
Only 14% of 51 AZA treated patients achieved remission [8,17],
and 30% deceased (27/89) [8,9,17,18]. The therapy of PRED + AZA
in 44 patients yielded a remission rate of 43% and a mortality rate
of 7% [8,18]. Remission rates of PRED treated patients versus
PRED + AZA treated patients yielded a comparable rate
(RR = 0.98; 95% CI 0.65–1.47). Neither of 33 patients randomized
for placebo achieved remission, and 13 patients (39%) died
[8,18]. One study assessed 27 patients with no intervention, the
remission rate could not be extracted and the mortality rate wasTreatment
duration
Patients
(n)
Remission
(%)
Mortality
(%)
Jadad
score
30–72 months 22
27
–
–
14
56
2
nce
3 months–3.5 years 18 44 6 4
14 7 36
14 21 7
17 0 41
2 years 22
25
–
–
5
24
3
nce
36 months 30 37 10 1
30 53 7
31 10 7
29 (16/13) – 41 (38/46)
38 (12–83) months 37* 16 27 2
47* 45 28
nts prednisone for 1 year, 27 patients azathioprine for 1 year. 13 patients who were
azathioprine group.
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Fig. 2. Effect of prednisone and azathioprine in autoimmune hepatitis
treatment. (A) Induction therapy naive AIH patients. (B) Induction therapy relapse
AIH patients. (C) Maintenance therapy AIH patients.
Review56% [7]. One study evaluating the effect of titrated PRED showed
no beneﬁt [18].
Induction therapy in AIH patients who relapsed
Four studies, with a Jadad score between 2 and 4, assessed the
clinical outcome of induction therapy in AIH patients who194 Journal of Hepatology 20relapsed (Table 2) [8,9,14,15]. In total, these 4 studies included
163 patients (22% males) in 7 different arms. The most important
comparators were similar to the studies in naive patients: PRED
(15–60 mg/day) versus AZA (75–100 mg/day) or a combination
of these two (PRED 10–30 mg/day, AZA 50 mg/day) versus mono-
therapy [8,9,15]. One study compared ursodeoxycholic acid
(UDCA 13–15 mg/kg/day) with placebo in PRED treated patients,
and UDCA showed no additional value [14]. A total of 32% from
34 PRED treated patients obtained remission [8,14], 4% died
(Fig. 2B) [8,9,14]. Twenty-two patients treated with PRED + AZA
achieved remission in 45% and had a corresponding mortality of
5% [8,15]. Treatment with PRED or with PRED + AZA was not dif-
ferent (RR = 0.71; 95% CI 0.37–1.39). Two studies focused on
AZA treatment [8,9]. Only 7% reached remission [8], and 28% died
[8,9]. For comparison, none of the patients who received placebo
came into remission, and there was an associated mortality of
41% [8].
Maintenance therapy in AIH patients
We identiﬁed 4 clinical trials that focused on AIH patients in
remission on maintenance therapy (Table 3) [12,13,16,19]. These
studies included 162 patients in 6 different arms, of which 22%
were male. Three studies scored 3 on the Jadad scale [12,13,19],
one study scored 1 [16]. One study compared AZA (2 mg/kg/day)
with PRED (5–12.5 mg/kg/day) + AZA (1 mg/kg/day) [13], another
study compared this combination ((PRED 5–10 mg/kg/day) + (AZA
50–100 mg/day)) with PRED (5–12.5 mg/day) [12]. Two trials
compared either thymostimulin with no intervention or PRED
(15 mg/day) with D-penicillamine [16,19]. Thymostimulin and
D-penicillamine had no relevant clinical value. PRED + AZA yielded
a higher rate of maintaining remission (96%) [12,13] than PRED
(68% [12,19], RR = 1.40; 95% CI 1.13–1.73). A total of 92% of AZA
treated patients maintained remission (Fig. 2C) [13]. Maintenance
treatment with PRED + AZA is not better than with AZA (RR = 1.06;
95% CI 0.94–1.20). AZA also maintained a higher remission rate
than PRED (RR = 1.35; 95% CI 1.07–1.70). In all studied treatment
groups none deceased [12,13,19].
Adverse events
Frequencies and percentages of reported adverse events were not
adequately mentioned in most studies. Patients receiving PRED
had a number of well known steroid related adverse events such
as cushingoid appearance, diabetes mellitus, hypertension, and
cataracts (Table 4). Adverse events associated with AZA treatment
were gastrointestinal bleeding, leucopenia, trombopenia, and
arthralgia. Cushingoid appearance and diabetes mellitus were
adverse events associated with the combination therapy
PRED + AZA, but in a lower reported frequency than PRED mono-
therapy. We found no differences in adverse event incidence
between treatment indications (naive, relapse or remission).Discussion
This systematic review evaluates the evidence that is available for
the induction and maintenance therapy in AIH.
Results from our analysis show that both PRED monotherapy
and PRED + AZA are better in achieving remission and limiting
mortality in treatment naive AIH patients than any other treat-10 vol. 53 j 191–198
Table 2. Induction therapy in patients with autoimmune hepatitis who relapsed.
First author, journal, year Intervention Treatment
duration
Patients
(n)
Remission
(%)
Mortality
(%)
Jadad
score
Soloway, Gastroenterology, 1972 Prednisone 60 mg/day 1 week, 40 mg/day
1 week, 30 mg/day 2 weeks, 20 mg/day maintenance
3 months –3.5 years 18 44 6 4
Azathioprine 100 mg/day 14 7 36
Prednisone 30 mg/day 1 week, 20 mg/day
1 week, 15 mg/day 2 weeks, 10 mg/day/week
maintenance + azathioprine 50 mg/day
14 21 7
Placebo 17 0 41
Murray-Lyon, Lancet, 1973 Prednisone 5 mg 3dd 2 years 22 – 5 3
Azathioprine 75 mg 1dd 25 – 24
Czaja, Hepatology, 1993 Oral pulse prednisone 90 mg/day for
5 consecutive days, every 28 days
Indeﬁnite 8 0 0 3
Prednisone 30 mg/day 1 week, 20 mg/day
1 week, 15 mg/day 2 weeks,
10 mg/day/week + azathioprine 50 mg/day
8 88 0
Czaja, Hepatology, 1999 UDCA 13–15 mg/kg/day + usual
corticosteroid schedule
6 months 21 14 5 2
Placebo + usual corticosteroid schedule 16 19 0
JOURNAL OF HEPATOLOGYment option evaluated in the literature between 1950 and July
2009. The efﬁcacy of both strategies seems similar, and the lower
mortality rate with PRED or PRED + AZA is an important additional
argument to favor this therapy over AZA monotherapy for the ini-
tial treatment of both naive and relapsing patients.
For patients who require maintenance therapy, the combina-
tion PRED + AZA and AZA monotherapy provides higher mainte-
nance rates of persistent remission compared to PRED
monotherapy. Testament to this is that mortality was absent with
either choice. Although AIH is much more prevalent in females,
we could not discern a gender difference in efﬁcacy for either nai-
ves, relapsers or patients in remission.
Surprisingly, the number of RCTs describing the clinical efﬁ-
cacy of different treatment strategies in AIH patients is low. We
only found 11 RCTs published between 1950 and July 2009. For
comparison, between July 2008 and July 2009 alone, already
around 150 clinical trials in hepatitis C were reported in the
literature. Moreover, studies were heterogeneous, performed dec-
ades apart with an evolving set of diagnostic criteria and no
proper evidence based deﬁnition for remission until 1999. In order
to offer recommendations for optimal induction and maintenanceTable 3. Maintenance therapy for autoimmune hepatitis patients in remission.
First author, journal, year Intervention
Stern, Gut,
1977
D-Penicillamine 1.2 g/day
Prednisone 15 mg/day
Hegarty, Gut,
1984
Thymostimulin 1 mg/kg/day i.m. for 7 days;
1 mg/kg/weekly thereafter
No therapy
Stellon, Lancet,
1985
Prednisolone 5–10 mg/day +
Azathioprine 50–100 mg/day
Prednisolone 5–12.5 mg/day
Stellon, Hepatology,
1988
Azathioprine 2 mg/kg/day
Azathioprine 1 mg/kg/day +
Prednisolone 5–12.5 mg/day
1 One patient died in a road accident, inclusion group unknown.
Journal of Hepatology 20treatment in AIH, we performed a descriptive analysis of the pub-
lished RCTs.
The question is whether we need future RCTs with currently
available treatment options in AIH. We believe that there is a large
unmet need. The trials that established the current standard
PRED + AZA stem from an era with different, and currently consid-
ered suboptimal, laboratory diagnostics. In addition, the epidemi-
ology of AIH probably has shifted. Due to improved diagnostics
AIH is probably diagnosed in a much earlier phase, and patients
that were considered to have AIH at the time of the earlier trials
will currently receive an alternative diagnosis. Thus, there is a
need for trials that reﬂects and beneﬁts the current AIH patient.
This brings us to the design of these future trials. Inclusion of a
placebo arm for induction treatment of either naive or relapsing
AIH is probably unethical. The remission rates with placebo are
poor (<12%), and earlier trials have shown that this strategy is
associated with signiﬁcant mortality [7,8,16,18]. We concur that
the therapy of AIH with PRED with or without AZA is far from
ideal, and the search for drugs with a favorable risk–beneﬁt ratio
is ongoing [20]. For most of the alternative approaches in the past,
the results have been disappointing and the adverse effects severeTreatment
duration
Patients
(n)
Remission
(%)
Mortality
(%)
Jadad
score
1 year 18
17
50
65
0
0
3
Indeﬁnite 13 16 0 1
17 12 0
3 years 23 96 01 3
27 70 01
1 year 25 92 0 3
22 100 0
10 vol. 53 j 191–198 195
Review
[20]. Recently, a German study group compared combined budes-
onide and AZA treatment to PRED + AZA in 208 AIH patients.
Remarkably this trial alone includes 25% of all AIH patients
included in a RCT to date. The primary endpoint of the study
was complete remission in absence of typical steroid-induced
adverse effects [21,22]. Preliminary results indicate that budeso-
nide is an efﬁcacious alternative to PRED, with a more favorable
side effect proﬁle. Less adverse events were experienced com-
pared to the data that we presented here. However, results haveTable 4. Adverse events.
First author,
journal, year
Intervention Treatment
duration
Cook, Quarterly
J. of Medicine,
1971
Prednisolone 15 mg Indeﬁnite
Soloway,
Gastroenterology,
1972
Prednisone 60 mg/day 1 week, 40 mg/day
1 week, 30 mg/day 2 weeks, 20 mg/day
maintenance
3 months–
3.5 years
Murray-Lyon Lancet,
1973
Prednisone 5 mg 3dd 2 years
Summerskill, Gut,
1975
Prednisone 60 mg/day 1 week, 40 mg/day
1 week, 30 mg/day 2 weeks, 20 mg/day
maintenance
36 months
Summerskill, Gut,
1975
Prednisone in doses titrated
given on alternated days
36 months
Tage-Jensen, Liver
1982
Prednisone <70 kg, 10 mg/day,
>70 kg, 15 mg/day
38 (12–83)
Stellon, Lancet, 1985 Prednisolone 5–12.5 mg/day 3 years
Czaja, Hepatology,
1993
Oral pulse prednisone 90 mg/day
for 5 consecutive days, every 28 days
Indeﬁnite
Soloway,
Gastroenterology,
1972
Prednisone 30 mg/day 1 wk, 20 mg/day
1 wk, 15 mg/day 2 wks,
10 mg/day/wk + AZT 50 mg/day
3 months–
3.5 years
Summerskill, Gut,
1975
Prednisone 30 mg/day 1 wk, 20 mg/day
1 wk, 15 mg/day 2 wks,
10 mg/day/wk + AZT 50 mg/day
36 months
Stellon, Lancet,
1985
Prednisolone 5–10 mg/day + azathioprine
50–100 mg/day
3 years
Stellon, Hepatology,
1988
Prednisolone 5–12.5 mg/day + azathioprine
1 mg/kg/day
1 year
Czaja, Hepatology,
1993
Prednisone 60 mg/day 1 week, 40 mg/day
1 week, 30 mg/day 2 weeks,
20 mg/day maintenance
Indeﬁnite
Soloway,
Gastroenterology,
1972
Azathioprine 100 mg/day 3 months–3
Murray-Lyon, Lancet
1973
Azathioprine 75 mg 1dd 2 years
Summerskill, Gut,
1975
Azat hioprine 100 mg/day 36 months
Tage-Jensen, Liver
1982
Azathioprine 10 mg/day/week,
ﬁrst 2 weeks 5 mg/kg/week
38 (12–83)
Stellon, Hepatology,
1988
Azathioprine 2 mg/kg/day 1 year
196 Journal of Hepatology 20only been published in abstract-form and long-term results of
budesonide are awaited.
In general, the results from our systematic analysis accord with
the current guidelines, which advise PRED or PRED + AZA for naive
AIH patients [1,6,10,20]. The combination regimen is the preferred
treatment because it is associated with a lower occurrence of cor-
ticosteroid-related adverse events than the higher dose PRED reg-
imen (10% versus 44%) [18,20]. However, in individual patients,
therapy is best tailored to the patient’s presentation [20]. ForPatients (n) Adverse events (n)
22 Severe: osteoporosis + vertebral collapse (2),
perforated duodenal ulcer (1),
acute steroid psychosis (1),
terminal bronchopneumoniae (1).
Mild: obesity (5), facial ‘‘mooning” (5),
acne (4), myositis (1)
18 Cushingoid appearance (13),
diabetes requiring insulin (1),
GI-bleeding (1), spinal collapse, aseptic
necrosis of hip, or cataracts (3)
22 –
30 Severe cosmetic changes, diabetic
mellitus cataracts, hypertension
31 Diabetes mellitus, diabetes mellitus
and hypertension, haematemesis/melaena
months 47 –
27 -
8 None
14 Cushingoid appearance (10)
30 Diabetes mellitus, haematemesis
23 None
22 Arthralgias (1)
8 Severe adverse events of
azathioprine not observed
.5 years 14 Cushingoid appearance (2), GI – bleeding (3),
spinal collapse, aseptic necrosis of hip,
or cataracts (1), leucopenia/thrombocyto (2),
ascites + 2 increase in bilirubin (>6 mg/100 ml) (2)
25 –
13 –
months 37 –
25 Arthralgia most hinged joints (14),
myalgias (7), transient leucopenia (1),
pancytopenia (2)
10 vol. 53 j 191–198
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adults who have relapsed more than once the AASLD advises to be
treated with PRED + AZA therapy, low dose PRED, or AZA only
[10]. Current maintenance regimens include PRED + AZA or AZA
[4,10]. Many AIH patients who have been in complete remission
for at least one year with PRED + AZA can remain in remission
with a higher dose of AZA alone [23]. Altogether, we can conclude
that our results in all three categories match with the current
guidelines.
This review has some limitations. A standardized, universally
accepted deﬁnition of remission in AIH patients exists since
1999. All articles that are part of this review were published in
or prior to 1999, and could consequently not match the overall
deﬁnition.
Apart from differences in deﬁnition of remission, the trials
described in the included articles used various doses of PRED
and AZA. Therefore, we were not able to abstract the best dose
for the highest remission rates using a systematic review.
Moreover, variations in medication schemes, outcome mea-
sures, and validity of trials introduced heterogeneity between
included studies. Another limitation is that only 11 RCTs have
been published since 1950. The current literature is replete with
reviews reﬂecting personal opinion, but lacks well executed RCTs.
In addition, most studies include a small number of patients.
Indeed, current therapy guidelines are based on 11 trials with only
578 patients reﬂecting the perpetual lack of evidence. In the same
vein we note that there is also a paucity of structured and system-
atic recording of adverse events with AIH therapy.
Current literature indicates remission rates of 65–80% [24], but
we found much lower percentages. The early RCTs in the 1970s
that established the efﬁcacy of corticosteroids in the treatment
of AIH included severe cases of AIH with severe, rapidly progres-
sive disease. Consequently, these studies contained more patients
with cirrhosis, which led to worse treatment outcomes and a
higher mortality rate. Patients with less severe disease probably
have not been included in the controlled clinical trials [25]. Data
on mild AIH are missing from the literature, and this introduces
a potential source of bias. Furthermore, the hepatitis C virus was
identiﬁed in 1989 [21]. Thus, AIH patients diagnosed prior to
1989 could have hepatitis C, and probably some patients were
inadvertently included in the initial trials. This could translate in
a lower remission rate. In addition, we did not take into account
the lead time bias, which also may affect the achievement of
remission and mortality.
In conclusion, PREDmonotherapy and PRED + AZA combination
therapy are equivalent in efﬁcacy for induction treatment in naive
and relapsing AIH patients. For maintenance therapy PRED + AZA
combination and AZA monotherapy are superior to PRED mono-
therapy. Alternative proposed strategies, in patients who have
failed to achieve remission on standard therapy or patients with
drug toxicity, are very welcome to optimize treatment.
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